Chemistry Department, Faculty of Science, Damietta University, Damietta, 34517, New-Damietta, Egypt.
Department of Laboratories, Immunology Laboratory, Mansoura University Children's Hospital, Mansoura, Egypt.
Drugs R D. 2024 Jun;24(2):303-316. doi: 10.1007/s40268-024-00479-1. Epub 2024 Jul 16.
Cancer is a deadly disease with high mortality rates in developing countries. A recent preclinical study found promising results in treating hepatocellular carcinoma (HCC) by combining acetylsalicylic acid (ASA) and ascorbate (AS), which might offer a safer alternative to expensive clinical chemotherapeutics; however, the impact of this combination on other tumors remains unexplored. Therefore, this study aims to investigate the effectiveness of combining ASA and AS in treating Ehrlich solid tumors.
Eighty female Swiss albino mice were divided into eight groups (10 mice/group): four healthy groups (healthy, AS, ASA, and AS+ASA) and four groups with carcinoma (Ehrlich ascites carcinoma [EAC], EAC+AS, EAC+ASA, and EAC+AS+ASA). AS was injected intraperitoneally (4 g/kg) daily for 10 days, whereas ASA was ingested orally at 60 mg/kg/day for 10 days. Carcinoma was induced by subcutaneous injection of 1×10 EAC cells/mouse once. Treatment of carcinoma started after 10 days of tumor inoculation. Blood, livers, and tumors were obtained, and tumor weights, volumes, and levels of hemoglobin, aminotransferases, albumin, bilirubin, urea, creatinine, lipid profile, malondialdehyde, nitric oxide, glutathione, catalase, total antioxidant capacity, lactate dehydrogenase, and creatine kinase were estimated. The percentage increase in lifespan was also assessed.
Tumor treatment alleviated tumor burden. Tumor size was reduced, lifespan increased, organs (liver, kidney, and heart) functions adjusted, hemoglobin, lipid profile improved, and oxidative stress decreased. Combining ASA with AS showed more effective antitumor effects than only ASA or AS alone.
After more validation research, combining ASA with AS may provide benefit in cancer treatment.
癌症是一种在发展中国家死亡率较高的致命疾病。最近的一项临床前研究发现，联合使用乙酰水杨酸（ASA）和抗坏血酸（AS）治疗肝细胞癌（HCC）有可喜的结果，这可能为昂贵的临床化疗提供更安全的替代方案；然而，这种联合治疗对其他肿瘤的影响仍未得到探索。因此，本研究旨在探讨联合使用 ASA 和 AS 治疗艾氏腹水瘤的效果。
将 80 只雌性瑞士白化病小鼠分为 8 组（每组 10 只）：4 个健康组（健康、AS、ASA 和 AS+ASA）和 4 个癌组（艾氏腹水癌[EAC]、EAC+AS、EAC+ASA 和 EAC+AS+ASA）。AS 每天腹腔内注射（4 g/kg），共 10 天；ASA 每天口服 60mg/kg，共 10 天。EAC 细胞以 1×10 个/只的剂量皮下注射诱导癌，肿瘤接种后第 10 天开始治疗癌。采集血液、肝脏和肿瘤，测定肿瘤重量、体积及血红蛋白、氨基转移酶、白蛋白、胆红素、尿素、肌酐、血脂、丙二醛、一氧化氮、谷胱甘肽、过氧化氢酶、总抗氧化能力、乳酸脱氢酶和肌酸激酶水平，评估寿命延长率。
肿瘤治疗减轻了肿瘤负担。肿瘤体积缩小，寿命延长，器官（肝、肾和心脏）功能得到调节，血红蛋白、血脂得到改善，氧化应激降低。ASA 联合 AS 比单独使用 ASA 或 AS 具有更有效的抗肿瘤作用。
经过更多的验证研究，联合使用 ASA 和 AS 可能会为癌症治疗带来益处。
